t
Disseminated via PRN on 10 October 2025
10 October 2025
4basebio PLC
("4basebio" or the "Company")
Result of Extraordinary General Meeting
Cambridge, UK, 10 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that all of the resolutions proposed at its Extraordinary General Meeting held earlier today were duly passed.
For further enquiries, please contact:
| 4basebio PLC | +44 (0)12 2396 7943 |
|
Dr. Heikki Lanckriet, CEO |
|
| Cairn Financial Advisers LLP (Nominated Adviser ) | +44 (0)20 7213 0880 |
|
Jo Turner / Sandy Jamieson / Ed Downes |
|
| Cavendish Capital Markets Limited ( Joint Broker) | +44 (0)20 7220 0500 |
|
Geoff Nash / Nigel Birks |
|
| RBC Capital Markets (Joint Broker) | +44 (0) 20 7653 4000 |
|
Kathryn Deegan / Matthew Coakes |
|
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.
